Diagnostic Approach of Lung Cancer: A Literature Review
Downloads
Lung cancer is the second most commonly diagnosed malignancy with the highest mortality rate. It can be classified into small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). At the early stage of the disease, lung cancer rarely gives apparent symptoms. Patients are usually diagnosed at an advanced stage. Lung cancer is closely related to tobacco smoking. The increasing prevalence of tobacco smoking in Indonesia should be an alarm. During the last decades, knowledge and technology regarding lung cancer screening and diagnosis have vastly increased. Proper screening for high-risk individuals will help to increase the survival rate from the disease. Diagnosis of lung cancer using various radiologic modalities, histopathology, and biomolecular tests will also determine a specific treatment approach for the patient. A proper diagnostic test will also help predict the patient's prognosis. This literature review aimed to provide foundation knowledge from recent guidelines for screening and diagnosing lung cancer.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209–249.
Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Heal; 85. Epub ahead of print January 2019.
Dartanto T, Moeis FR, Can CK, et al. Good Intentions, Unintended Outcomes: Impact of Social Assistance on Tobacco Consumption in Indonesia. Tob Induc Dis 2021; 19: 1–16.
Cancer IA for R on. Thoracic Tumours. 5th ed. France: World Health Organization, https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 (2021).
Carter BW, Erasmus JJ. Current Concepts in the Diagnosis and Staging of Lung Cancer. In: Hodler J, Kubik-Huch RA, von Schulthess GK (eds). Cham (CH), 2019, pp. 79–93.
Wang X, Wang Z, Pan J, et al. Patterns of Extrathoracic Metastases in Different Histological Types of Lung Cancer. Front Oncol 2020; 10: 715.
Upadhya P, Ananthraju A, Vadala R, et al. Endocrine Paraneoplastic Syndromes in Lung Cancer: A Respiratory Physician's Perspective. Adv Respir Med 2021; 89: 403–412.
Nwagbara UI, Ginindza TG, Hlongwana KW. Health Systems Influence on the Pathways of Care for Lung Cancer in Low- and Middle-Income Countries: A Scoping Review. Global Health 2020; 16: 23.
Aini SR, Wulandari L, Andajani S. Lung Cancer Patients' Profile in Dr Soetomo General Hospital Surabaya 2016 - 2017: Newest Report. JUXTA J Ilm Mhs Kedokt Univ Airlangga 2019; 10: 44–47.
Soetandyo N, Hanafi AR, Agustini S, et al. Prognosis of Advanced Stage Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy: Sdenocarcinoma versus Squamous Cell Carcinoma. Med J Indones; 29. Epub ahead of print 26 March 2020.
Surveillance, Epidemiology and ER (SEER) P. Lung and Bronchus SEER Relative Survival Rates by Time Since Diagnosis. Bethesda, https://seer.cancer.gov/.
Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer with Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021; 325: 971–987.
Field JK, Vulkan D, Davies MPA, et al. Lung Cancer Mortality Reduction by LDCT Screening: UKLS Randomised Trial Results and International Meta-Analysis. Lancet Reg Heal – Eur; 10. Epub ahead of print 1 November 2021.
Hunger T, Wanka-Pail E, Brix G, et al. Lung Cancer Screening with Low-Dose CT in Smokers: A Systematic Review and Meta-Analysis. Diagnostics (Basel, Switzerland); 11. Epub ahead of print June 2021.
Brodersen J, Voss T, Martiny F, et al. Overdiagnosis of Lung Cancer with Low-Dose Computed Tomography Screening: Meta-Analysis of the Randomised Clinical Trials. Breathe (Sheffield, England) 2020; 16: 200013.
Lebrett MB, Balata H, Evison M, et al. Analysis of Lung Cancer Risk Model (PLCO(M2012) and LLP(v2)) Performance in a Community-Based Lung Cancer Screening Programme. Thorax 2020; 75: 661–668.
Tammemägi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 Lung Cancer Screening Eligibility Criteria (International Lung Screening Trial): Interim Analysis of a Prospective Cohort Study. Lancet Oncol 2022; 23: 138–148.
Rampinelli C, De Marco P, Origgi D, et al. Exposure to Low Dose Computed Tomography for Lung Cancer Screening and Risk of Cancer: Secondary Analysis of Trial Data and Risk-Benefit Analysis. BMJ 2017; 356: j347.
Nekolla EA, Brix G, Griebel J. Lung Cancer Screening with Low-Dose CT: Radiation Risk and Benefit–Risk Assessment for Different Screening Scenarios. Diagnostics; 12. Epub ahead of print 2022.
Wood DE, Kazerooni EA, Aberle D, et al. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. J Natl Compr Canc Netw 2022; 20: 754–764.
Larici AR, Farchione A, Franchi P, et al. Lung Nodules: Size still Matters. Eur Respir Rev 2017; 26: 170025.
PasÅ‚awski M, Krzyzanowski K, ZÅ‚omaniec J, et al. Morphological Characteristics of Malignant Solitary Pulmonary Nodules. Ann Univ Mariae Curie Sklodowska Med 2004; 59: 6–13.
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017; 284: 228–243.
Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung Cancer Probability in Patients with CT-Detected Pulmonary Nodules: A Prespecified Analysis of Data from the NELSON Trial of Low-Dose CT Screening. Lancet Oncol 2014; 15: 1332–1341.
Zhang R, Tian P, Chen B, et al. Predicting Lung Cancer Risk of Incidental Solid and Subsolid Pulmonary Nodules in Different Sizes. Cancer Manag Res 2020; 12: 8057–8066.
Snoeckx A, Reyntiens P, Desbuquoit D, et al. Evaluation of the Solitary Pulmonary Nodule: Size Matters, but Do Not Ignore the Power of Morphology. Insights Imaging 2018; 9: 73–86.
Huang Y-H, Hsu K-H, Tseng J-S, et al. Predilection of Contralateral Upper Lung Metastasis in Upper Lobe Lung Adenocarcinoma Patients. J Thorac Dis 2016; 8: 86–92.
Panunzio A, Sartori P. Lung Cancer and Radiological Imaging. Curr Radiopharm 2020; 13: 238–242.
Kanashiki M, Tomizawa T, Yamaguchi I, et al. Volume Doubling Time of Lung Cancers Detected in a Chest Radiograph Mass Screening Program: Comparison with CT Screening. Oncol Lett 2012; 4: 513–516.
de Margerie-Mellon C, Ngo LH, Gill RR, et al. The Growth Rate of Subsolid Lung Adenocarcinoma Nodules at Chest CT. Radiology 2020; 297: 189–198.
Yang X, Wisselink HJ, Vliegenthart R, et al. Association between Chest CT-defined Emphysema and Lung Cancer: A Systematic Review and Meta-Analysis. Radiology 2022; 304: 322–330.
Gershman E, Zer A, Pertzov B, et al. Characteristics of Lung Cancer in Idiopathic Pulmonary Fibrosis with Single Lung Transplant versus Non-Transplanted Patients: A Retrospective Observational Study. BMJ Open Respir Res; 7. Epub ahead of print June 2020.
Kim HC, Lee S, Song JW. Impact of Idiopathic Pulmonary Fibrosis on Clinical Outcomes of Lung Cancer Patients. Sci Rep 2021; 11: 8312.
Radiology AC of. Lung-RADS 2022: Summary of Changes and Updates. Virginia, https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/Lung-RADS-2022-Summary-_Final.pdf (2022).
Rossi G, Graziano P. Lung Cancer Diagnosis. J Xiangya Med J Xiangya Med; 7, https://jxym.amegroups.com/article/view/8223 (2022).
Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-Cell Lung Cancer. Nat Rev Dis Prim 2021; 7: 3.
Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and Classification of SCLC. Cancers (Basel); 13. Epub ahead of print February 2021.
Herbst RS, Morgensztern D, Boshoff C. The Biology and Management of Non-Small Cell Lung Cancer. Nature 2018; 553: 446–454.
Clark SB, Alsubait S. Non Small Cell Lung Cancer. Treasure Island (FL), 2023.
Shim HS, Choi Y-L, Kim L, et al. Molecular Testing of Lung Cancers. J Pathol Transl Med 2017; 51: 242–254.
Dalurzo ML, Avilés-Salas A, Soares FA, et al. Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. Onco Targets Ther 2021; 14: 4671–4692.
Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the . Arch Pathol Lab Med 2018; 142: 321–346.
Nan X, Xie C, Yu X, et al. EGFR TKI as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Oncotarget 2017; 8: 75712–75726.
Chung C-H. EGFR Tyrosine Kinase Inhibitor Therapy for Lung Cancer Treatments and Their Clinical Outcomes: A Cohort Study in Taiwan. Oncol Lett 2019; 18: 6090–6100.
Sutandyo N, Suratman E. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. Acta Med Indones 2018; 50: 291–298.
Mithoowani H, Febbraro M. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Curr Oncol 2022; 29: 1828–1839.
Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 2020; 383: 2018–2029.
D'Angelo A, Sobhani N, Chapman R, et al. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers (Basel); 12. Epub ahead of print November 2020.
Rojo F, Conde E, Torres H, et al. Clinical and Economic Impact of ‘ROS1-Testing' Strategy Compared to a ‘No-ROS1-Testing' Strategy in Advanced NSCLC in Spain. BMC Cancer 2022; 22: 292.
Greenspan BS. Role of PET/CT for Precision Medicine in Lung Cancer: Perspective of the Society of Nuclear Medicine and Molecular Imaging. Transl Lung Cancer Res 2017; 6: 617–620.
Sim AJ, Kaza E, Singer L, et al. A Review of the Role of MRI in Diagnosis and Treatment of Early Stage Lung Cancer. Clin Transl Radiat Oncol 2020; 24: 16–22.
Health Commission Of The People's Republic Of China N. National Guidelines for Diagnosis and Treatment of Lung Cancer 2022 in China (English Version). Chin J Cancer Res 2022; 34: 176–206.
Copyright (c) 2023 Jesi Hana, Novia Nurul Faizah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (